Search

Your search keyword '"Chaouche-Teyara, Kamel"' showing total 13 results
Start Over Author "Chaouche-Teyara, Kamel"
13 results on '"Chaouche-Teyara, Kamel"'

3. Steroid avoidance with early intensified dosing of enteric-coated mycophenolate sodium: a randomized multicentre trial in kidney transplant recipients

Author

Thierry, Antoine, Mourad, Georges, Büchler, Matthias, Kamar, Nassim, Villemain, Florence, Heng, Anne-Elisabeth, Le Meur, Yannick, Choukroun, Gabriel, Toupance, Olivier, Legendre, Christophe, Lepogamp, Patrick, Kessler, Michele, Merville, Pierre, Moulin, Bruno, Quéré, Stéphane, Terpereau, Arara, Chaouche-Teyara, Kamel, and Touchard, Guy

Published
2012
Full Text
View/download PDF

4. Secukinumab for moderate to severe palmoplantar pustular psoriasis: Results of the 2PRECISE study

Author

Mrowietz, Ulrich, Bachelez, Hervé, Burden, A. David, Rissler, Michael, Sieder, Christian, Orsenigo, Roberto, and Chaouche-Teyara, Kamel

Abstract

Palmoplantar pustular psoriasis (PPP) is a debilitating disease of the palms and/or soles that is resistant to treatment. Secukinumab, an anti-IL-17A monoclonal antibody, is highly efficacious in the treatment of moderate to severe psoriasis. The primary objective was ppPASI75 response with secukinumab at Week 16 vs. placebo (2.5% significance level). 2PRECISE was a phase 3b multicenter, randomized, double-blind, placebo-controlled, parallel-group study comparing secukinumab 300 mg (n=79) and 150 mg (n=80) to placebo (n=78) in subjects with moderate to severe PPP over 52 Weeks. The primary endpoint was not met. At Week 16, 26.6% of subjects with secukinumab 300 mg achieved ppPASI75 vs.. 14.1% with placebo (P=0.0411) [OR: 2.62; 95% CI: 1.04, 6.60]. At Week 52, 41.8% of subjects with secukinumab 300mg had ppPASI75. More DLQI 0/1 responses were achieved with secukinumab 300 mg (13.0%) vs. placebo (4.3%) at Week 16. At Week 52, 43.1% of subjects receiving secukinumab 300 mg had DLQI 0/1. No unexpected adverse events were observed. Small sample size and characteristics of PPP disease course. PPP patients treated with secukinumab 300 mg showed benefit in ppPASI75 responses over 52 weeks and improved quality of life. [Abstract copyright: Copyright © 2019. Published by Elsevier Inc.]

Published
2019

5. Renal function with delayed or immediate cyclosporine microemulsion in combination with enteric-coated mycophenolate sodium and steroids: results of follow up to 30 months post-transplant

Author

Mourad, Georges, Karras, Alexandre, Kamar, Nassim, Garrigue, Valérie, Legendre, Christophe, Lefrançois, Nicole, Charpentier, Bernard, Bourbigot, Bernard, Pouteil-Noble, Claire, Bayle, François, Lebranchu, Yvon, Mariat, Christophe, Le Meur, Yann, Kessler, Michèle, Moulin, Bruno, Ducloux, Didier, Delahousse, Michel, Lang, Philippe, Merville, Pierre, Chaouche-Teyara, Kamel, and Rostaing, Lionel

Published
2007

13. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study.

Author

Mrowietz U, Bachelez H, Burden AD, Rissler M, Sieder C, Orsenigo R, and Chaouche-Teyara K

Subjects
Adult, Aged, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Humanized, Dermatologic Agents administration & dosage, Dermatologic Agents adverse effects, Double-Blind Method, Female, Humans, Male, Middle Aged, Patient Reported Outcome Measures, Quality of Life, Severity of Illness Index, Antibodies, Monoclonal therapeutic use, Dermatologic Agents therapeutic use, Psoriasis drug therapy
Abstract

Background: Palmoplantar pustular psoriasis (PPP) is a debilitating disease of the palms and/or soles that is resistant to treatment. Secukinumab, an anti-interleukin 17A monoclonal antibody, is highly efficacious in the treatment of moderate-to-severe psoriasis., Objective: The primary objective was to determine the rate of achievement of a 75% improvement from baseline in Palmoplantar Psoriasis Area and Severity Index (PPPASI75) with secukinumab at week 16 versus with placebo (at a 2.5% significance level)., Methods: 2PRECISE was a phase 3b multicenter, randomized, double-blind, placebo-controlled, parallel-group study comparing treatment with 300 mg of secukinumab (n = 79), 150 mg of secukinumab (n = 80), and placebo (n = 78) in subjects with moderate-to-severe PPP over a period of 52 weeks., Results: The primary end point was not met. At week 16, 26.6% of subjects treated with 300 mg of secukinumab achieved PPPASI75 versus 14.1% of those who received placebo (P = .0411) (odds ratio, 2.62; 95% confidence interval, 1.04-6.60). At week 52, 41.8% of subjects treated with 300 mg of secukinumab had achieved ppPASI75. More Dermatology Life Quality Index responses of 0 or 1 were achieved with 300 mg of secukinumab (13.0%) than with placebo (4.3%) at week 16. At week 52, 43.1% of subjects receiving 300 mg of secukinumab had a Dermatology Life Quality Index response of 0 or 1. No unexpected adverse events were observed., Limitations: Small sample size and characteristics of the PPP disease course., Conclusion: Patients with PPP who were treated with secukinumab, 300 mg, showed benefit in terms of PPPASI75 responses over 52 weeks and improved quality of life., (Copyright © 2019 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results